Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the June 30, 2010 issue of Managing Intellectual Property titled “Federal Circuit to re-hear biotech cases post-Bilski.” Brinckerhoff discusses the Supreme Court’s decision to grant certiorari, and then vacate and remand biotech patent case Prometheus v Mayo in light of the decision issued in Bilski v. Kappos. She states that the contested patents in Prometheus should survive since the Federal Circuit has already found that they meet the machine-or-transformation test, but notes that the Bilski decision includes some troubling points for biotech and pharmaceutical patents. She adds that assessing whether a particular patent might promote or impede innovation as a way of determining patent eligibility could be a slippery slope.
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“